The advent of molecularly targeted agents, such as the inhibitors of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), is providing some innovative avenues for tailored treatment selection and personalized therapeutic interventions [8, 9], offering both challenges and opportunities in accurately diagnosing, classifying, and managing gliomas. Here, VEGFA is linked to glioma.